The Wisconsin Alumni Research Foundation (WARF) will allow Pfizer Inc. to use some of its patented human embryonic stem cell lines for the development of new drug therapies.
WARF, the private, nonprofit patenting and licensing arm of the University of Wisconsin-Madison, announced the signing of the licensing agreement Tuesday. Janet Kelly, a spokesperson for WARF, said financial terms of the deal were confidential.